Making the Connection: Between Patients and Providers An Integrative Approach to the Treatment of Type 1 and Type 2 Diabetes

Making the Connection: Between Patients and Providers, An Integrative Approach to the Treatment of Type 1 and Type 2 Diabetes is organized by Taking Control of Your Diabetes (TCOYD).

Term Offering: This activity was released on 5/23/2022 and is valid for one year. Requests for credit must be made no later than 5/23/2023.

This CME program is a 4-Lecture Series on Core Diabetes Topics

• Effective Use of Oral Medications for Type 2 Diabetes: Lowering Cardio-renal Risk While Improving Glycemic Control
• Focus on Time in Range and Modern Management of Type 1 Diabetes
• Injectable Agents and Cardiovascular Effects
• Diabetes Distress: What it is, Why it is important, and What to Do About It

Get on the same page as your patients with diabetes to improve adherence and persistence, avoid acute complications, and improve long-term outcomes.

This program is led by two endocrinologists living with diabetes themselves and a faculty of experts in the diabetes field. This program will provide real case studies and cutting-edge strategies to help you with helping your patients with diabetes reach their treatment goals. Get access to impactful research and practical steps to open two-way communication with your patients with diabetes and improve outcomes.

Program Topics:
We focus on four distinct areas of the most cutting-edge diabetes management strategies:
•  Patient-provider relationships with a focus on communication methods to improve adherence and persistence 
•  Oral agents for the treatment of type 2 diabetes and their effect on cardiovascular and renal health 
•  Injectable therapies, including insulin, for use in patients with type 2 diabetes and their cardiovascular and obesity impact
•  Time in range, adjunctive therapies, hybrid closed loop systems, and the unmet needs of type 1 diabetes

Learning Objectives:
Upon completion of these activities, participants should be able to:
1. Identify the different pathophysiologic defects associated with type 2 diabetes and how all the pharmacologic agents (oral and injectable) to address these specific abnormalities including patients with very poor glycemic control and elevated insulin requirements.
2. Discuss the recently published cardiovascular-renal outcome trials on oral (SGLT2 inhibitors) and injectable type 2 medications (GLP1-RAS). 
3. Evaluate the use of SGLT-2 and GLP-1 RA in patients who have cardiovascular risk factors and are at risk or have a history of atherosclerotic cardiovascular disease (ASCVD).
4. Design a treatment plan for multiple daily injection regimens and insulin pump therapy including hybrid closed-loop systems. 
5. Select effective therapeutic adjustments based on CGM trending or rate of change arrows, time in range, and standard deviation. 
6. Recognize the physical and emotional barriers that prevent patients with diabetes from being persistent and adherent to their therapeutic regimen(s). 
7. Discuss innovative and dynamic strategies for communication with patients to strengthen provider-patient relations.